Definitive Healthcare (NASDAQ:DH) Stock Rating Upgraded by Wall Street Zen

Definitive Healthcare (NASDAQ:DH - Get Free Report) was upgraded by Wall Street Zen from a "hold" rating to a "buy" rating in a research note issued on Saturday.

A number of other analysts have also commented on DH. Barclays reduced their price target on shares of Definitive Healthcare from $4.00 to $3.00 and set an "underweight" rating for the company in a research note on Monday, March 3rd. The Goldman Sachs Group boosted their price target on Definitive Healthcare from $3.00 to $3.40 and gave the company a "neutral" rating in a report on Monday, May 12th. Finally, BTIG Research cut shares of Definitive Healthcare from a "buy" rating to a "neutral" rating in a research note on Friday, May 9th. Two investment analysts have rated the stock with a sell rating, seven have assigned a hold rating and two have assigned a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus price target of $5.10.

Definitive Healthcare Stock Up 0.8%

Definitive Healthcare stock traded up $0.03 during mid-day trading on Friday, hitting $4.00. The company had a trading volume of 1,253,370 shares, compared to its average volume of 798,534. Definitive Healthcare has a 12 month low of $2.15 and a 12 month high of $6.16. The company has a market capitalization of $594.56 million, a PE ratio of -0.91, a price-to-earnings-growth ratio of 6.61 and a beta of 1.58. The stock's 50 day moving average price is $3.20 and its two-hundred day moving average price is $3.67. The company has a current ratio of 1.75, a quick ratio of 1.75 and a debt-to-equity ratio of 0.37.

Definitive Healthcare (NASDAQ:DH - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The company reported $0.05 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.02 by $0.03. The company had revenue of $59.19 million for the quarter, compared to analysts' expectations of $56.20 million. Definitive Healthcare had a negative net margin of 206.05% and a positive return on equity of 3.69%. Definitive Healthcare's revenue was down 6.8% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.08 EPS. As a group, sell-side analysts anticipate that Definitive Healthcare will post 0.16 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Definitive Healthcare

Several institutional investors have recently bought and sold shares of DH. Goldman Sachs Group Inc. raised its position in Definitive Healthcare by 564.2% in the 1st quarter. Goldman Sachs Group Inc. now owns 8,716,725 shares of the company's stock worth $25,191,000 after purchasing an additional 7,404,363 shares during the period. Irenic Capital Management LP raised its holdings in shares of Definitive Healthcare by 9.2% in the fourth quarter. Irenic Capital Management LP now owns 7,003,194 shares of the company's stock worth $28,783,000 after buying an additional 590,009 shares during the period. Palisade Capital Management LP lifted its stake in shares of Definitive Healthcare by 1.3% during the 1st quarter. Palisade Capital Management LP now owns 2,265,198 shares of the company's stock worth $6,546,000 after acquiring an additional 29,774 shares during the last quarter. Dimensional Fund Advisors LP boosted its holdings in Definitive Healthcare by 1.3% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,863,912 shares of the company's stock valued at $7,661,000 after acquiring an additional 23,410 shares during the period. Finally, Geode Capital Management LLC grew its position in Definitive Healthcare by 3.2% in the 4th quarter. Geode Capital Management LLC now owns 1,272,660 shares of the company's stock valued at $5,231,000 after acquiring an additional 39,938 shares during the last quarter. Institutional investors own 98.67% of the company's stock.

Definitive Healthcare Company Profile

Definitive Healthcare Corp., together with its subsidiaries, provides software as a service (SaaS) healthcare commercial intelligence platform in the United States and internationally. Its SaaS platform provides information on healthcare providers and their activities to help its customers from product development to go-to-market planning, and sales and marketing execution.